学会場(国際会議場)に隣接する運河とナロウボート
21th International Congress of Chemotherapy
Birmingham, UK - July 4 - July 7, 1999
SPFX ON CAM COMBINED TREATMENT FOR LRTI WITH CHRONIC RESPIRATORY FAILURE
Toshiyuki Sawa, Tutomu Yoshida, Teturoh Ikoma, Miki Toyoda*, Kohshi Goto*, Hisayoshi Fujiwara*
Gifu Municipal Hospital, *Gifu University, Gifu, Japan
Introduction: As lower respiratory tract infection (LRTI) is one of the fatal complications for the elderly patient with chronic respiratory failure, it is important to control LRTI for the outpatients treated with home-oxygen therapy. Sparfloxacin (SPFX) is an oral new-quinolone derivative thought to be effective to LRTI, and Clarithromycin (CAM) has another various biological effects as well as antibiotics. Thus it is expected that SPFX and CAM may act synergistic effects bacteriologically. We investigated the clinical efficacy and safety of additional SPFX on CAM combined treatment for LRTI in the patients with chronic respiratory failure.
Method: 38 patients were enrolled in this study, and in the 9 patients in whom 400mg/day of oral CAM during 2 weeks have failed to eradicate causative organisms, 100mg/day of additional oral SPFX on CAM was given during one week. The concentration of SPFX in serum and sputum were measured at 4, 12, 24, 48 and 168 hours after SPFX on CAM combined treatment.
Results: The clinical efficacy rate was 44.4% (4/9 patients), and the bacteriological eradication rate was 55.6% (5/9 strains). Mean serum concentration of SPFX was 0.29-0.67 μg/ml and penetration rate from serum to sputum was 88.4 - 128.9%. The adverse events, anorexia, GOT elevation and luecopenia in each one case, were tolerable to perform the treatment with SPFX and CAM.
It is concluded that oral SPFX and CAM combined treatment is useful to control LRTI in the elderly patients with chronic respiratory failure without hospitalization.
北ウェールズの古城の塔屋上にて